Canada Markets close in 4 hrs 38 mins

Windtree Therapeutics, Inc. (WINT)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
0.1998+0.0153 (+8.29%)
As of 11:22AM EST. Market open.

Windtree Therapeutics, Inc.

2600 Kelly Road
Suite 100
Warrington, PA 18976-3622
United States
215 488 9300
https://windtreetx.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees33

Key Executives

NameTitlePayExercisedYear Born
Mr. Craig E. FraserPres, CEO & Director584.62kN/A1965
Mr. John P. Hamill CPASr. VP, CFO, Treasurer & Corp. Sec.472.51kN/A1964
Dr. Steven G. SimonsonSr. VP & Chief Medical Officer514.3kN/A1959
Mr. Eric L. Curtis M.B.A.Sr. VP & COON/AN/A1969
Mr. George CoxVP of Technical OperationsN/AN/A1952
Ms. Diane Carman Esq.Sr. VP & Gen. CounselN/AN/A1969
Dr. Pratap ParuchuruExec. Director of Clinical Devel.N/AN/AN/A
Ms. Tracy RarickHead of Operations & Program ManagementN/AN/AN/A
Dr. Ronald L. DundoreExec. Director of Regulatory Affairs & QualityN/AN/A1955
Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Windtree Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of acute cardiovascular and secondarily in acute pulmonary diseases. The company's lead development programs include istaroxime, which is in Phase IIb clinical trial for the treatment of acute decompensated heart failure, as well as in Phase IIa clinical trial for the treatment of early cardiogenic shock; AEROSURF, an aerosolized KL4 surfactant, which is in Phase IIb clinical trial to treat respiratory distress syndrome in premature infants; Lyophilized KL4 surfactant, which is in Phase IIa clinical trial for the treatment of lung injury resulting from COVID-19; and Rostafuroxin that is in Phase IIb clinical trial for the treatment of genetically associated hypertension. It has a collaboration with Universita degli Studi di Milano-Bicocca for the discovery and development of new SERCA2a compounds for the treatment of chronic and acute human heart failure; a strategic alliance with Laboratorios del Dr. Esteve, S.A. for the development, marketing, and sales of a portfolio of potential KL4 surfactant products; and collaboration with Battelle Memorial Institute for development of its ADS for use in its phase III program. The company was formerly known as Discovery Laboratories, Inc. and changed its name to Windtree Therapeutics, Inc. in April 2016. Windtree Therapeutics, Inc. was incorporated in 1992 and is headquartered in Warrington, Pennsylvania. Windtree Therapeutics, Inc. is a subsidiary of Lee's Pharmaceutical Holdings Limited.

Corporate Governance

Windtree Therapeutics, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.